Loading...
XASX
AGN
Market cap57mUSD
Aug 08, Last price  
0.69AUD
1D
0.73%
1Q
-8.00%
IPO
60.47%
Name

Argenica Therapeutics Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
34.12
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
3m
+48.46%
0296,075259,0981,749,8992,597,937
Net income
-5m
L+13.80%
-383,403-1,029,501-4,090,752-4,815,044-5,479,488
CFO
-5m
L+53.34%
-58,817-1,046,408-3,361,673-3,300,316-5,060,561

Profile

Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.
URL
https://argenica.com.au/
IPO date
Jun 11, 2021
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑06
Income
Revenues
2,598
48.46%
1,750
575.38%
Cost of revenue
8,269
6,625
Unusual Expense (Income)
NOPBT
(5,671)
(4,875)
NOPBT Margin
Operating Taxes
(2,089)
(1,378)
Tax Rate
NOPAT
(3,582)
(3,497)
Net income
(5,479)
13.80%
(4,815)
17.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,634
3,725
BB yield
-14.35%
-11.34%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(15,913)
(9,339)
Cash flow
Cash from operating activities
(5,061)
(3,300)
CAPEX
Cash from investing activities
50
(50)
Cash from financing activities
11,634
3,725
FCF
(3,582)
(3,497)
Balance
Cash
15,913
9,339
Long term investments
Excess cash
15,783
9,252
Stockholders' equity
13,951
7,666
Invested Capital
(659)
ROIC
530.61%
ROCE
EV
Common stock shares outstanding
103,707
87,578
Price
0.78
108.53%
0.38
 
Market cap
81,099
146.94%
32,842
 
EV
65,186
23,503
EBITDA
(5,671)
(4,875)
EV/EBITDA
Interest
1
Interest/NOPBT